pifogyxat.blogspot.com
The Cystic Fibrosis Centert at the hospital is the first site to beginm recruiting patients forthe 48-week international clinical triakl to test the VX-770 drug developed by Vertec Pharmaceuticals Inc. of Cambridge, Mass. Cystic fibrosisa is a genetic disease that affectsapproximatelty 30,000 people in the U.S. and 70,000 people Mutations of the cystic fibrosia genecauses life-threatening lung The Buffalo site of the trial, called STRIVE, will enrolk people 12 and old who carry a mutatiobn known as G551D in the CF gene. Ultimately, 80 sited will be involved in the trial. The local studyg will be overseenby Dr.
Drucgy Borowitz, director of the CF center and chieft of the pediatric pulmonology division at the She is also professor of pediatrics in the Schook of Medicine andBiomedicalp Sciences. Vertex will conduct three differen clinical trials as part of the registratiohn program for the drug involving approximately110 sites. The currentf study is a phase three trial, the fina step before a successfuol drug may be submitted to the forpotential Additionally, another 48-week phase three tria is recruiting children between 6 and 12; and a 16-weekl trial will be conducted for the firs time in patients with another common mutatioh of the gene, F508del.
Borowitz’s center will also participatw inthat study, expected to begin in the thirs quarter of 2009. According to the Boston Business a sister publication ofBusiness First, VX-77o0 was discovered as part of a collaboratiobn with , the nonprofit drug discovery and developmenty affiliate of the Cystic Fibrosis The Foundation has invested more than $320 million in drug research in the biotechh industry since 1998.
Vertex retains worldwids rights to develop and commercialize the if it gainsregulatory
No comments:
Post a Comment